Singapore Institute of Advance (9G2) Fair Value & Analysis
Healthcare · SG · Market cap 48.3M SGD
Fair value as of: Aug 13, 2026
From 1 valuation models · updated 4 days ago
Fair value updated Aug 13, 2026, revised from 0.0264 SGD to 0.0258 SGD (−2.2%) since Aug 9, 2026. Share price +7.4% over the past month.
Below-average quality, and screening another 11% overvalued on our models.
What matters now
- The models converge in a tight band (0.0258 SGD to 0.0286 SGD), unusually little disagreement for a valuation.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
30‑month range 0.0250 SGD – 0.1900 SGD · fair‑value band 0.0258 SGD – 0.0286 SGD · the 0.0290 SGD price screens above the 0.0258 SGD fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Singapore Institute of Advance (9G2) currently trades at 0.0290 SGD, while our model-based Fair Value estimate is 0.0258 SGD, implying the stock looks roughly 11.0% overvalued today. The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 16.2M SGD. Revenue declined 0.1% year over year. It earns a return on equity of -51.0%. Net debt stands at 25.4M SGD. Fundamentals as of Aug 13, 2026
Our scenario range runs from 0.0258 SGD (bear case) to 0.0286 SGD (bull case); at 0.0290 SGD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 67% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -11%, 9G2 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 9G2 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 35 · Market factors (momentum, volatility) 25
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Singapore Institute of Advanced Medicine Holdings Ltd., an investment holding company, provides medical diagnostics and treatments, and radiation therapy and medical oncology services in Singapore.
Full company description
Singapore Institute of Advanced Medicine Holdings Ltd., an investment holding company, provides medical diagnostics and treatments, and radiation therapy and medical oncology services in Singapore. The company offers medical diagnostics and treatments, including cancer-related diagnostics and theragnostic treatments, general diagnostics and health screening, and aesthetic services; and radiation therapy and medical oncology services comprise proton beam therapy, photon radiation therapy, and medical oncology services. It provides clinic and imaging services; manufactures medical research and clinical diagnostic instruments and supplies; and sells pharmaceuticals, surgical products, and consumables. Singapore Institute of Advanced Medicine Holdings Ltd. was incorporated in 2011 and is based in Singapore.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
Singapore Institute of Advance reported revenue of 15.7M SGD in FY2025 versus 13.8M SGD in FY2022, a compound +4.4%/yr. Reported net income was −26.2M SGD in FY2025.
9G2 screens 11% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 267 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $414.59 | $547.67 | +32% |
| Fresenius SE FRE | €46.82 | €32.15 | -31% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | -46% |
| Tenet Healthcare Corporation THC | $266.79 | $330.25 | +24% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.97 | R$47.31 | +39% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,565 | ₹2,955 | -65% |
| Aier Eye Hospital Group 300015 | ¥8.87 | ¥7.67 | -14% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,008 | ₹284.87 | -72% |
| Bangkok Dusit Medical Services Public Company BDMS | 19.70 THB | 18.57 THB | -6% |
Compare Singapore Institute of Advance with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Singapore Institute of Advance (9G2) overvalued or undervalued?
What is the fair value of 9G2?
What is the quality score of 9G2?
What is the revenue of Singapore Institute of Advance (9G2)?
What is the net profit margin of 9G2?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Singapore Institute of Advance and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.